m****g 发帖数: 530 | 1 Cubist Pharmaceuticals to End Development of CB-500,929
From the PharmaLive.com News Archive - Mar. 31, 2010
Decision follows review of Phase 2 top line results
LEXINGTON, Mass.--(BUSINESS WIRE)--Mar 31, 2010 - Cubist Pharmaceuticals,
Inc. (NASDAQ: CBST) today
announced that it plans to stop investing in the clinical development of CB-
500,929 (ecallantide) as a
therapy to reduce blood loss in patients undergoing cardiac surgery using
cardiopulmonary bypass. The
company made this decision after |
|